vulva or vulvar cancer? - nm

Does the patient have prostate cancer - One possibility

I think they are talking about the doctor conducting the trial study:

(I only copied the pertinent parts)

http://prostablog.wordpress.com/older-stuff/medical-journals/new-england-journal-prostate-articles/

New England Journal of Medicine, June, 2009

Duration of androgen suppression in the treatment of prostate cancer

Michel Bolla, M.D., Theodorus M. de Reijke, M.D., Ph.D., Geertjan Van Tienhoven, M.D., Ph.D., Alphonsus C.M. Van den Bergh, M.D., Ph.D., Jorg Oddens, M.D., Philip M.P. Poortmans, M.D., Ph.D., Eliahu Gez, M.D., Paul Kil, M.D., Ph.D., Atif Akdas, M.D., Guy Soete, M.D., Oleg Kariakine, M.D., Elsbietha M. van der Steen-Banasik, M.D., Elena Musat, M.D., Marianne Piérart, M.S., Murielle E. Mauer, Ph.D., Laurence Collette, Ph.D., for the EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group

Conclusions: The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer. (ClinicalTrials.gov number, NCT00003026 [ClinicalTrials.gov] .)

The European Organization for Research and Treatment of Cancer (EORTC) conducted a trial (EORTC protocol 22961) to determine whether short-term androgen suppression would both preserve quality of life and achieve the overall survival rate obtained with long-term androgen suppression.

With a median follow-up of 6.4 years, we found no serious long-term genitourinary or gastrointestinal toxicity from radiotherapy and no increase in the risk of fatal cardiovascular events. In an updated analysis of protocol 22863, the EORTC group reported a 10-year risk of death from cardiac events of 6% in the group receiving radiotherapy and long-term androgen suppression as compared with 4.2% in the group receiving radiotherapy alone.

In the early 1990s Bolla et al. began exploring the use of androgen-deprivation therapy in a different setting: adjuvant therapy in men with clinically advanced localized disease who were scheduled to receive radiation therapy.⁶

References
6. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-108. [CrossRef][ISI][Medline]

agree with the above poster -- - Bolla